MX2020008360A - Forma cristalina de bictegravir sodico. - Google Patents

Forma cristalina de bictegravir sodico.

Info

Publication number
MX2020008360A
MX2020008360A MX2020008360A MX2020008360A MX2020008360A MX 2020008360 A MX2020008360 A MX 2020008360A MX 2020008360 A MX2020008360 A MX 2020008360A MX 2020008360 A MX2020008360 A MX 2020008360A MX 2020008360 A MX2020008360 A MX 2020008360A
Authority
MX
Mexico
Prior art keywords
crystalline form
bictegravir sodium
pharmaceutical composition
relates
present
Prior art date
Application number
MX2020008360A
Other languages
English (en)
Inventor
Hannes Lengauer
Arthur Pichler
Renate Margreiter
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of MX2020008360A publication Critical patent/MX2020008360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

La presente invención se refiere a una forma cristalina de bictegravir sódico y a un proceso para su preparación. Además, la invención se refiere a una composición farmacéutica que comprende dichaf orma cristalina de bictegravir sódico, preferiblemente en una cantidad predeterminada y/o eficaz, al menos un excipiente farmacéuticamente aceptable y opcionalmente uno o más agentes antivirales adicionales. La composición farmacéutica de la presente invención se puede utilizar como un medicamento, en particular para el tratamiento y/o profilaxis de infecciones por VIH-1.
MX2020008360A 2018-02-09 2019-01-25 Forma cristalina de bictegravir sodico. MX2020008360A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156094 2018-02-09
EP18194234 2018-09-13
PCT/EP2019/051818 WO2019154634A1 (en) 2018-02-09 2019-01-25 Crystalline form of bictegravir sodium

Publications (1)

Publication Number Publication Date
MX2020008360A true MX2020008360A (es) 2020-09-25

Family

ID=65234570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008360A MX2020008360A (es) 2018-02-09 2019-01-25 Forma cristalina de bictegravir sodico.

Country Status (10)

Country Link
EP (1) EP3749673B1 (es)
CN (1) CN111699190A (es)
AU (1) AU2019218837A1 (es)
BR (1) BR112020015217A2 (es)
CA (1) CA3088596A1 (es)
DK (1) DK3749673T3 (es)
ES (1) ES2916405T3 (es)
MX (1) MX2020008360A (es)
SI (1) SI3749673T1 (es)
WO (1) WO2019154634A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111978333B (zh) * 2019-09-30 2021-06-18 常州制药厂有限公司 Bictegravir钠盐的晶型A、制备方法及用途
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
CN112409380A (zh) * 2020-12-10 2021-02-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型的制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54873B1 (sr) 2012-12-21 2016-10-31 Gilead Sciences Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
EP3749673A1 (en) 2020-12-16
EP3749673B1 (en) 2022-03-16
ES2916405T3 (es) 2022-06-30
WO2019154634A1 (en) 2019-08-15
AU2019218837A1 (en) 2020-09-24
DK3749673T3 (da) 2022-06-20
CA3088596A1 (en) 2019-08-15
CN111699190A (zh) 2020-09-22
SI3749673T1 (sl) 2022-07-29
BR112020015217A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MY192607A (en) Antiviral beta-amino acid ester phosphodiamide compounds
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2019012884A (es) Terapia de combinacion.
MX2020008360A (es) Forma cristalina de bictegravir sodico.
IN2013MU03583A (es)
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
MX2021002321A (es) Nuevos metodos.
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2021002322A (es) Nuevos metodos.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2022002331A (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
IN2013CH05288A (es)
MX2018012210A (es) Glucono delta-lactona para el tratamiento de infecciones fungicas vaginales.
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия
MX2018012952A (es) Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo.
AR108792A1 (es) Composiciones que comprenden timolol
MX2019015480A (es) Preparacion medicinal combinada para tratar infecciones virales.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.